Invitae Stock: Approach With Caution

Shares of genetic testing company Invitae (NYSE: NVTA) have surged more than 40% over the past month, a combination of improving investor sentiment toward growth stocks as well as the company's preliminary release of financial results for 2022. Investors need to know about this upcoming event and consider the potential ramifications before buying shares. Earlier this past summer, Invitae's management announced plans to exit non-core businesses to push the company toward positive cash flow.